Welcome to our dedicated page for Inozyme Pharma SEC filings (Ticker: INZY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INZY SEC filings page on Stock Titan compiles U.S. Securities and Exchange Commission documents historically filed by Inozyme Pharma, Inc., which traded on the Nasdaq Global Select Market under the symbol INZY before its acquisition by BioMarin Pharmaceutical Inc. These filings trace Inozyme’s life cycle as a public company, from its status as a clinical-stage biopharmaceutical issuer through its change of control, delisting, and deregistration.
Key transaction-related filings include a Form 8-K dated July 1, 2025, reporting the completion of BioMarin’s acquisition of Inozyme pursuant to an Agreement and Plan of Merger. This filing explains that a BioMarin subsidiary merged with and into Inozyme, with Inozyme continuing as the surviving corporation and becoming a wholly owned subsidiary of BioMarin. The same Form 8-K describes the tender offer at $4.00 per share in cash and the subsequent conversion of remaining shares into the right to receive the same consideration.
For trading status, a Form 25 filed on July 1, 2025, by Nasdaq Stock Market LLC documents the removal of Inozyme’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A Form 15 filed on July 11, 2025, then certifies the termination of registration of Inozyme’s common stock under Section 12(g) and the suspension of its duty to file periodic reports under Sections 13 and 15(d). Together, these filings confirm that INZY is a delisted and deregistered security.
Earlier periodic and current reports, such as Forms 10-K, 10-Q, and 8-K referenced in Inozyme’s press releases, provide additional context on the company’s clinical-stage operations, including its focus on the PPi-Adenosine Pathway, development of INZ-701 for ENPP1 and ABCC6 Deficiencies, and financial position prior to the acquisition. While those documents are accessed directly through the SEC’s EDGAR system, this page highlights the most material items for understanding INZY’s regulatory history.
Stock Titan enhances access to these filings with AI-powered summaries that explain the purpose and implications of each document in plain language. Users can quickly see how specific Forms 8-K relate to the merger and delisting, how the Form 25 and Form 15 altered Inozyme’s reporting obligations, and how the company’s disclosures fit into the broader narrative of its transition from an independent public issuer to a BioMarin subsidiary. This makes the INZY filings page a practical resource for anyone researching historical corporate actions, listing status changes, and the regulatory record associated with Inozyme Pharma’s former public listing.
Inozyme Pharma COO Matthew Winton acquired 14,355 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP). The shares were purchased at $0.74 per share, representing 85% of the closing price on April 1, 2025, the first day of the purchase period.
Following this transaction, Winton's direct beneficial ownership increased to 21,743 shares. The purchase was made during the ESPP period running from April 1, 2025, through June 25, 2025.
- Transaction Type: Stock Purchase through ESPP
- Purchase Price: $0.74 per share (15% discount)
- Ownership Form: Direct
- Filing Status: Individual filing
This insider purchase through the ESPP demonstrates continued participation in company equity programs by key executive leadership.
Insider Trading Alert: Douglas A. Treco, CEO & Chairman of Inozyme Pharma (NASDAQ: INZY), acquired 2,815 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key Transaction Details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- Total shares owned after transaction: 43,861 shares
- Ownership type: Direct
- ESPP purchase period: April 1, 2025 - June 25, 2025
The transaction was executed under the company's 2020 ESPP, which allows employees to purchase company stock at a discount. This insider purchase by the CEO demonstrates continued alignment with shareholder interests and potential confidence in the company's prospects.
Inozyme Pharma (INZY) SVP, CFO & Head of BD Sanjay Subramanian reported the acquisition of 6,813 shares of common stock on June 25, 2025, through the company's Employee Stock Purchase Plan (ESPP).
Key transaction details:
- Purchase price: $0.74 per share (85% of closing price on April 1, 2025)
- ESPP purchase period: April 1, 2025 - June 25, 2025
- Total shares owned after transaction: 39,701 shares
- Ownership form: Direct
This insider purchase through the ESPP demonstrates continued participation in company equity programs by a key executive officer. The transaction was executed under the company's 2020 Employee Stock Purchase Plan, which allows employees to purchase shares at a discount to market price.
Inozyme Pharma has announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, 2025, due to a pending acquisition by BioMarin Pharmaceutical. If the acquisition completes, no public stockholder annual meeting will be held. If it doesn't proceed, the Board will reschedule the meeting with a new record date.
Key Company Profile:
- Clinical-stage biopharmaceutical company with ~50 Boston-based employees
- Focuses on PPi-Adenosine Pathway therapeutics for bone health and blood vessel function
- Lead therapy INZ-701, an ENPP1 Fc fusion protein, is in late-stage clinical trials
- Target conditions include ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis
The filing includes detailed information about the tender offer process and directs stockholders to review important acquisition-related documents filed with the SEC by both companies. Materials are available on the SEC website and both companies' respective websites.
Inozyme Pharma, Inc. (Nasdaq: INZY) filed a Form 8-K on June 20, 2025 to disclose that it has postponed its 2025 Annual Meeting of Stockholders in light of the previously announced acquisition by BioMarin Pharmaceutical Inc. The decision is detailed in a press release attached as Exhibit 99.1; an Inline XBRL cover-page file is included as Exhibit 104.
The report stresses that the tender-offer process is governed by documents already on file with the SEC: BioMarin and Incline Merger Sub’s Schedule TO (Offer to Purchase, Letter of Transmittal and related materials) and Inozyme’s Schedule 14D-9 Solicitation/Recommendation Statement. Investors are urged to review these materials, which are available without charge on www.sec.gov and the companies’ investor-relations websites.
No financial statements, operating metrics or earnings information accompany this current report. The filing is limited to the postponement notice and related procedural information regarding the pending transaction.
FAQ
What is the current stock price of Inozyme Pharma (INZY)?
What is the market cap of Inozyme Pharma (INZY)?
